Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ORION CORPORATION STOCK EXCHANGE RELEASE 5 FEBRUARY 2013 at 1.50 PM EET The Board of Directors of Orion Corporation has decided on a new share-based incentive plan for the Group key persons. The aim...
-
ORION CORPORATION STOCK EXCHANGE RELEASE 5 FEBRUARY 2013 at 12.15 EET The Board of Directors of Orion Corporation has decided today to convene the Annual General Meeting of the Shareholders of Orion...
-
ORION CORPORATION FINANCIAL STATEMENT RELEASE 2012 5 FEBRUARY 2013 at 12:00 noon EET Orion's net sales in 2012 totalled EUR 980 million (EUR 918 million in 2011), up by 7% on the previous...
-
ORION OYJ PÖRSSITIEDOTE 22.1.2013 KLO 10.00 Orion julkaisee tilinpäätöstiedotteen vuodelta 2012 tiistaina 5.2.2013 noin klo 12.00. Sekä suomen- että englanninkielinen tiedote ja...
-
Orion Corporation Stock Exchange Release 21 January 2013 at 12.35 p.m. EET The Nomination Committee of Orion Corporation has given on 21 January 2013 its recommendation to the...
-
ORION CORPORATION STOCK EXCHANGE RELEASE 21 JAN 2013 AT 10:00 a.m. EET In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act, Orion Corporation publishes an Annual...
-
ORION CORPORATION STOCK EXCHANGE RELEASE 16 January 2013 AT 9.20 AM EET In accordance with Section 3 of the Articles of Association of Orion Corporation, 31,900 A-shares have been converted into...
-
ORION CORPORATION STOCK EXCHANGE RELEASE 20 DECEMBER 2012 at 11:22 EET Orion Corporation ("Orion") and Mylan Pharmaceuticals Inc. ("Mylan") have executed a settlement agreement on lawsuit...
-
ORION CORPORATION STOCK EXCHANGE RELEASE 20 DECEMBER 2012 at 9.25 EET In accordance with Section 3 of the Articles of Association of Orion Corporation, 203,000 A-shares have been converted...
-
ORION CORPORATION STOCK EXCHANGE RELEASE 30 NOVEMBER 2012 at 1:10 PM EET Orion Corporation is developing a budesonide-formoterol formulation combining budesonide as an anti-inflammatory agent and...